Antiplatelet drug: Difference between revisions
Line 20: | Line 20: | ||
**[[Clopidogrel]] (Plavix) | **[[Clopidogrel]] (Plavix) | ||
**[[Ticlopidine]] (Ticlid) | **[[Ticlopidine]] (Ticlid) | ||
* P2Y<sub>12</sub> (Adenosine diphosphate receptors) inhibitors (thienopyridines) - third generation | * P2Y<sub>12</sub> (Adenosine diphosphate receptors) inhibitors (non-thienopyridines) - third generation | ||
**[[Prasugrel]] | **[[Prasugrel]] | ||
**[[Cangrelor]] | **[[Cangrelor]] |
Revision as of 03:56, 8 January 2019
WikiDoc Resources for Antiplatelet drug |
Articles |
---|
Most recent articles on Antiplatelet drug Most cited articles on Antiplatelet drug |
Media |
Powerpoint slides on Antiplatelet drug |
Evidence Based Medicine |
Cochrane Collaboration on Antiplatelet drug |
Clinical Trials |
Ongoing Trials on Antiplatelet drug at Clinical Trials.gov Trial results on Antiplatelet drug Clinical Trials on Antiplatelet drug at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Antiplatelet drug NICE Guidance on Antiplatelet drug
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Antiplatelet drug Discussion groups on Antiplatelet drug Patient Handouts on Antiplatelet drug Directions to Hospitals Treating Antiplatelet drug Risk calculators and risk factors for Antiplatelet drug
|
Healthcare Provider Resources |
Causes & Risk Factors for Antiplatelet drug |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
An antiplatelet drug is a member of a class of pharmaceuticals that decreases platelet aggregation and inhibits thrombus formation. They are effective in the arterial circulation, where anticoagulants have little effect.
They are widely used in primary and secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
The Most Important Antiplatelet Drugs
- COX-2 inhibitor / Cyclooxygenase inhibitors
- Phosphodiesterase inhibitors
- Cilostazol (Pletal)
- Glycoprotein IIB/IIIA inhibitors (intravenous use only)
- Abciximab (ReoPro)
- Eptifibatide (Integrilin)
- Tirofiban (Aggrastat)
- Defibrotide
- P2Y12 (Adenosine diphosphate receptors) inhibitors (thienopyridines)
- Clopidogrel (Plavix)
- Ticlopidine (Ticlid)
- P2Y12 (Adenosine diphosphate receptors) inhibitors (non-thienopyridines) - third generation